Phase II study of combination chemotherapy with irinotecan and cetuximab for pretreated metastatic colorectal cancer harboring wild-type KRAS

By Shitara Kohei   Yokota Tomoya   Takahari Daisuke   Shibata Takashi   Ura Takashi   Utsunomiya Setsuo   Inaba Yoshitaka   Yamaura Hidekazu   Sato Yozo   Najima Mina   Kawai Hiroki   Tajika Masahiro   Sawaki Akira   Yatabe Yasushi   Muro Kei  

Investigational New Drugs, Vol. 29, Iss. 4, 2011-08 ,pp. : 688-693

Springer Publishing Company

Access to resources Recommend Favorite

Biweekly cetuximab plus irinotecan as second-line chemotherapy for patients with irinotecan-refractory and KRAS wild-type metastatic colorectal cancer according to epidermal growth factor receptor expression status

By Kang Myoung  

Investigational New Drugs, Vol. 30, Iss. 4, 2012-08 ,pp. : 1607-1613

Springer Publishing Company

Access to resources Recommend Favorite

A phase II study of S-1 plus irinotecan and oxaliplatin in heavily-treated patients with metastatic colorectal cancer

By Kim Sun   Hong Yong   Kim Byung   Park Ji   Choi Hyo   Jeong Seung-Yong   Kim Dae   Hong Chang   Sohn Dae   Jung Kyung  

Investigational New Drugs, Vol. 27, Iss. 3, 2009-06 ,pp. : 269-274

Springer Publishing Company

Access to resources Recommend Favorite

A Phase Ib pharmacokinetic study of the anti-angiogenic agent CKD-732 used in combination with capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer patients who progressed on irinotecan-based chemotherapy

By Shin Sang  

Investigational New Drugs, Vol. 30, Iss. 2, 2012-04 ,pp. : 672-680

Springer Publishing Company

Access to resources Recommend Favorite

Phase II study of oral S-1 with irinotecan and bevacizumab (SIRB) as first-line therapy for patients with metastatic colorectal cancer

By Yamada Yasuhide  

Investigational New Drugs, Vol. 30, Iss. 4, 2012-08 ,pp. : 1690-1696

Springer Publishing Company

Access to resources Recommend Favorite